Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 766-771

  Paolucci, Stefania ^a   Baldanti, Fausto ^a   Zavattoni, Maurizio ^a   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

HIV 1 isolates; IC50; NNRTIs; NRTIs; Viral population

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SELECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; PLASMID; SUPERNATANT; VIRUS ISOLATION; VIRUS STRAIN;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLONING, MOLECULAR; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PHENOTYPE; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT FAILURE;

EID: 2442710266     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh165     Document Type: Article

References (17)

1. Paolucci, S., Baldanti, F., Tinelli, M. et al. (2003). Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy. AIDS 17, 924-7.
2. Baldanti, F., Paolucci, S., Maga, G. et al. (2003). Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. AIDS 17, 1568-70.
3. Blanca, G., Baldanti, F., Paolucci, S. et al. (2003). Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity. Journal of Biological Chemistry 278, 15469-72.
4. Ross, L., Scarsella, A., Raffanti, S. et al. (2001). Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Research and Human Retroviruses 17, 1107-15.
5. Menzo, S., Monachetti, A., Balotta, C. et al. (2003). Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 17, 663-71.
6. Iversen, A. K. N., Shafer, R. W., Wehrly, K. et al. (1996). Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Journal of Virology 70, 1086-90.
7. Larder, B. A., Bloor, S., Kemp, S. D. et al. (1999). A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrobial Agents and Chemotherapy 43, 1961-7.
8. Ross, L., Henry, K., Paar, D. et al. (2001). Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens. Journal of Human Virology 4, 217-22.
9. Japour, A. J., Mayers, D. L., Johnson, V. A. et al. (1993). Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 37, 1095-101.
10. Boucher, C., Keulen, W., van Bommel, T. et al. (1996). Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrobial Agents and Chemotherapy 40, 2404-9.
11. Hertogs, K., de Bethune, M. P., Miller, V. et al. (1998). A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents and Chemotherapy 42, 269-76.
12. Petropoulos, C. J., Parkin, N. T., Limoli, K. L. et al. (2000). A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 44, 920-8.
13. Cattaneo, E., Zavattoni, M., Baldanti, F. et al. (1999). Diagnostic value of viral culture, polymerase chain reaction and Western blot for HIV-1 infection in 218 infants born to HIV-infected mothers and examined at different ages. New Microbiologica 22, 281-91.
14. The AIDS Clinical Trials Group Virology Technical Advisory Committee and the Division of AIDS, National Institutes of Allergy and Infectious Diseases. (1994). In HIV Drug Susceptibility Assay. ACTG Virology Manual for HIV Laboratories. pp. RES 1-12. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA.
15. Paolucci, S., Baldanti, F., Campanini, G. et al. (2001). Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. Journal of Medical Virology 65, 207-17.
16. Betts, B. J. & Shafer, R. W. (2003). Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation. Journal of Clinical Microbiology 41, 2792-4.
17. Kantor, R., Machekano, R., Gonzales, M. J. et al. (2001). Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Research 29, 296-9.